Vorozole (Rivizor(TM)): An active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure

Anti-Cancer Drugs

Volumn 9, Issue 1, 1998, Pages 29-35

  Paridaens, Robert ^h   Roy, Jose A ^a   Nooij, Marianne ^b   Klijn, Jan ^c   Houston, Stephen J ^d   Beex, Louk V A M ^e   Vinholes, Jefferson ^a   Tomiak, Eva ^a   Van Vreckem, Ann ^a   Langenaeken, Christine ^f   Van Glabbeke, Martine ^a   Piccart, Martine J ^g  

^a EORTC DATA CENTER   (Belgium)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d GUY S HOSPITAL   (United Kingdom)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f JANSSEN RESEARCH FOUNDATION   (Belgium)

^g JULES BORDET INSTITUTE   (Belgium)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Aromatase; Breast cancer; Metastatic; Phase II; Postmenopausal; Vorozole

Indexed keywords

AMINOGLUTETHIMIDE; AROMATASE INHIBITOR; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; TAMOXIFEN; VOROZOLE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; TRIAZOLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; MALAISE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PRURITUS; SNEEZING; SOMNOLENCE; VERTIGO; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; MIDDLE AGED; NAUSEA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; NAUSEA; TAMOXIFEN; TRIAZOLES;

EID: 0031606490     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199801000-00003     Document Type: Article

References (16)

1. Mouridsen HT. Endocrine treatment of advanced breast cancer. In: Cavalli F, ed. Endocrine therapy of breast cancer. ESO Monographs, Berlin: Springer-Verlag 1986: 79-90.
2. Smith IE, Harris AL, Morgan M, Gazet JC, McKinna JA. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res 1982; 42: 3430-3.
3. Lipton A, Harvey HA, Santen RJ, et al. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res 1982; 42: 3434-6.
4. De Coster R, Wouters W, Bowden CR, et al. New non-steroidal aromatase inhibitors: focus on R76713. J Steroid Biochem Mol Biol 1990; 37: 335-41.
5. Wouters W, De Coster R, Beerens D, et al. Potency and selectivity of the aromatase inhibitor R 76 713. A study in human ovarian adipose stromal, testicular and adrenal cell. J Steroid Biochem 1990; 36: 57-65.
6. Wouters W, De Coster R, Van Dun J, et al. Comparative effects of the aromatase inhibitor R76713 and of its enantiomers R83839 and R83842 on steroid biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol 1990; 37: 1049-54.
7. van der Wall E, Donker TH, de Frankrijker E, Nortier HWR, Thijssen JHH, Blankenstein MA. Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women. Cancer Res 1993; 53: 4563-6.
8. Borms M, Vandebroeck J, Rutten J, et al. Vorozoleracemate (R76713): a specific non-steroidal aromatase inhibitor pilot study in advanced post-menopausal breast cancer. Eur J Cancer 1993; 29A: S84.
9. Johnston SRD, Smith IE, D Doody, Jacobs S, Robertshaw H, Dowsett M. Clinical and endocrine effects of the oral aromatase inhibitor Vorozole in postmenopausal patients with advanced breast cancer. Cancer Res 1994; 54: 5875-81.
10. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977; 13: 89-94.
11. Goss PE, Clark RM, Ambus U, et al. Phase II study of Vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clin Cancer Res 1995; 1: 287-94.
12. Paridaens R. Hormonal resistance in breast cancer. In Dickson RB, Lippman ME, eds. Drug and hormonal resistance in breast cancer: Cellular and molecular mechanisms. New York: Ellis Horwood 1995: 21-37.
13. Taylor IV SG, Gelman RA, Falkson G, Cummings FJ. Combination chemotherapy compared to Tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Int Med 1986; 104: 455-61.
14. Howell A, Downey S, Anderson E. New endocrine therapies for breast cancer. Eur J Cancer 1996; 32A: 576-88.
15. di Salle E, Ornati G, Paridaens R, Coombes RC, Lobelle JP, Zurlo MG. Preclinical and clinical pharmacology of the aromatase inhibitor exemestane (FCE 24304). In: Motta M, Serio M, eds. Sex hormones and antihormones in endocrine dependent pathology: basic and clinical aspects. Amsterdam: Elsevier Science 1994: 303-10.
16. Thürlimann B, Paridaens R, Roche H, et al. Exemestane in postmenopausal pretreated advanced breast cancer: a multicenter phase-II study in patients with aminogluthetamide (AG) failure. Ann Oncol 1994; 5 (suppl 8): 29.